COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is associated with acute respiratory distress syndrome, as well as extrapulmonary complications such as vascular thrombosis, coagulopathy, and a hyperinflammatory syndrome contributing to disease severity and mortality. SARS-CoV-2 infects target cells using the spike glycoprotein (S), which is organized as a ...

Aug 12th, 2021 - We report that there is a recent global expansion of numerous independent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with mutation L452R in the receptor-binding domain (RBD) of the spike protein. The massive emergence of L452R variants was first linked to lineage B.1.4...

Mar 21st, 2021 - Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been international concern about the emergence of virus variants with mutations that increase transmissibility, enhance escape from the human immune response, or otherwise alter biologically important phenotypes....

Sep 2nd, 2021 - Coronavirus disease 2019 (COVID-19), the highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a catastrophic effect on the world’s demographics resulting in more than 2.9 million deaths worldwide, emerging as the most consequential global health crisis since the ...

Feb 23rd, 2022 - SPL UNCLASSIFIED SECTION The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing...

Jan 28th, 2022 - Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance. To evaluate the capacity of Abbott...

Dec 2nd, 2022 - Using genomics, bioinformatics and statistics, herein we demonstrate the effect of statewide and nationwide quarantine on the introduction of SARS-CoV-2 variants of concern (VOC) in Hawai'i. To define the origins of introduced VOC, we analyzed 260 VOC sequences from Hawai'i, and 301,646 VOC sequences worldwide, deposited in the GenBank and global initiative on sharing all influenza data ...

Jul 18th, 2021 - COVID -19 is an acute viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 primarily affects the respiratory system; however, it can affect other major organ systems as well. Since the onset of the SARS-CoV-2 pandemic, multiple new variants ...

Jul 14th, 2022 - Viruses like SARS-CoV-2 continuously evolve as changes in the genetic code (caused by genetic mutations or viral recombination) occur during replication of the genome. A lineage is a genetically closely related group of virus variants derived from a common ancestor. A variant has one or more mutations that differentiate it from other variants of the SARS-CoV-...

Nov 3rd, 2021 - Español | Other Languages Key Points. Genetic lineages of SARS-CoV-2 have been emerging and circulating around the world since the beginning of the COVID-19 pandemic. SARS-CoV-2 genetic lineages in the United States are routinely monitored through epidemiological investigations, virus genetic sequence-based surveillance, and laboratory studies. The US g...

May 17th, 2022 - SPL UNCLASSIFIED SECTION HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA) These highlights of the EUA do not include all the information needed to use BEBTELOVIMAB under the EUA. See the FULL FACT SHEET FOR HEALTHCARE PROVIDERS for BEBTELOVIMAB. BEBTELOVIMAB injection for intravenous use Original EUA Authorized Date: 02/2...

Dec 21st, 2022 - SPL UNCLASSIFIED SECTION HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA) These highlights of the EUA do not include all the information needed to use EVUSHELD™ under the EUA. See the FULL FACT SHEET FOR HEALTHCARE PROVIDERS for EVUSHELD. EVUSHELD (tixagevimab) injection; (cilgavimab) injection, co-packaged for intramuscular use Original EUA Authorized Date: 12/2021 Revised EUA Authorized Date: ...

Jun 28th, 2022 - COVID-19 Science Update released: December 17, 2021 Edition 117 COVID-19 Science Update released: December 10, 2021 Edition 116 COVID-19 Science Update released: December 3, 2021 Edition 115 COVID-19 Science Update released: November 19, 2021 Edition 114 Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. Walter et al. NEJM (November 9,2021). Key findings: • In chil...

Jan 24th, 2022 - SPL UNCLASSIFIED SECTION TREATMENT The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved products bamlanivimab and etesevimab administered together for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-...

Dec 22nd, 2021 - SPL UNCLASSIFIED SECTION TREATMENT The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved products bamlanivimab and etesevimab administered together for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-...

Jun 28th, 2022 - An Update on the Ongoing Federal Response to COVID-19: Current Status and Future Planning House Veteran Affairs Subcommittee on Economic Opportunity [vc_row viewport_display="show-one,show-two,show-three,show-four,show-five,show-six"][vc_column][cdc_textbox box_style="plain" orientation="vertical" header_node_type="DIV" title_size="h4" title_margin="none" title_node_type="DIV" text_box_type="w...